Burcu Kolukisa

Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency

T. Chatila, D. Krappmann, N. Rezaei, 2022, Journal of Clinical Immunology.

Primary Immune Regulatory Disorders and Targeted Therapies.

S. Barış, Burcu Kolukisa, 2021, Turkish journal of haematology : official journal of Turkish Society of Haematology.

Immune dysfunction in inborn errors of immunity causing malignancies

S. Barış, Burcu Kolukisa, 2021, Expert review of clinical immunology.

Evolution and long‐term outcomes of combined immunodeficiency due to CARMIL2 deficiency

T. Chatila, H. Su, G. Baysoy, 2021, Allergy.

Consensus Middle East and North Africa Registry on Inborn Errors of Immunity

R. Geha, A. Bousfiha, W. Al-Herz, 2021, Journal of Clinical Immunology.

Adverse COVID‐19 outcomes in immune deficiencies: Inequality exists between subclasses

S. Barış, H. Artaç, F. Orhan, 2021, Allergy.

Evaluation of Clinical and Immunological Alterations Associated with ICF Syndrome.

S. Barış, E. Karakoc‐Aydiner, A. Kıykım, 2023, Journal of clinical immunology.

Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study

P. Chatchatee, K. Suphapeetiporn, J. Jalbert, 2024, The Lancet.

25 A phase 2/3 study evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE disease)

M. Lenardo, P. Chatchatee, Helen F. Matthews, 2023, Immunobiology.